Yan Yuting, Zhang Yan, Liu Mengting, Li Lingjie, Zheng Yanrong
Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, Jinhua Academy, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Int J Mol Sci. 2025 Mar 18;26(6):2722. doi: 10.3390/ijms26062722.
Growing neurochemical evidence highlights cerebral lipid dysregulation as a key factor in the pathophysiology of major depressive disorder (MDD). This review systematically explores the dual roles of lipid species in both normal behavioral regulation and MDD development. By critically examining the recent literature, we classify these lipid species into two functional categories based on their functional neuroactivity: (1) neuroprotective lipids (sphingomyelin, cholesterol, cardiolipin, sphingosine, phosphatidic acid, and phosphatidylserine), which exert neuroprotective effects by modulating membrane fluidity and supporting synaptic vesicle trafficking; and (2) neurotoxic lipids (ceramides, phosphatidylinositol, phosphocholine, and phosphatidylethanolamine), which promote apoptotic signaling cascades and disrupt mitochondrial bioenergetics. An unresolved but critical question pertains to the maintenance of homeostatic equilibrium between these opposing lipid classes. This balance is essential, given their significant impact on membrane protein localization and function, monoaminergic neurotransmitter metabolism, energy homeostasis, and redox balance in neural circuits involved in mood regulation. This emerging framework positions cerebral lipidomics as a promising avenue for identifying novel therapeutic targets and developing biomarker-based diagnostic approaches for MDD treatment.
越来越多的神经化学证据表明,脑脂质失调是重度抑郁症(MDD)病理生理学的关键因素。本综述系统地探讨了脂质种类在正常行为调节和MDD发展中的双重作用。通过严格审查近期文献,我们根据其功能神经活性将这些脂质种类分为两个功能类别:(1)神经保护脂质(鞘磷脂、胆固醇、心磷脂、鞘氨醇、磷脂酸和磷脂酰丝氨酸),它们通过调节膜流动性和支持突触小泡运输发挥神经保护作用;(2)神经毒性脂质(神经酰胺、磷脂酰肌醇、磷酸胆碱和磷脂酰乙醇胺),它们促进凋亡信号级联反应并破坏线粒体生物能量学。一个尚未解决但至关重要的问题涉及这些相反脂质类别之间稳态平衡的维持。鉴于它们对膜蛋白定位和功能、单胺能神经递质代谢、能量稳态以及情绪调节相关神经回路中的氧化还原平衡有重大影响,这种平衡至关重要。这个新兴框架将脑脂质组学定位为识别新治疗靶点和开发基于生物标志物的MDD治疗诊断方法的有前景途径。